title: Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
abstract: We have previously shown that in vivo genetic modification of tumors with an adenovirus (Ad) vector engineered to express CD40 ligand (AdmCD40L) induces tumor-specific CTLs and suppresses tumor growth in vivo. In the present study, we investigate the hypothesis that this treatment can be made more efficient with 10(2)-fold less Ad vector by also administering bone marrow-generated dendritic cells (DCs) to the tumor. Using AdmCD40L and the number of DCs that alone had no effect on tumor growth, the data show that the growth of CT26 (colon adenocarcinoma; H-2d) and B16 (melanoma; H-2b) murine s.c. tumors is significantly suppressed by direct administration of DCs into s.c. established tumors that had been pretreated with AdmCD40L 2 days previously. The antitumor effect produced by the combination therapy AdmCD40L + DCs correlated with in vivo priming of tumor-specific CTLs. The antitumor cell-mediated immunity was transferable to naive mice by spleen cells from AdmCD40L + DC-treated animals. The interactions between CD40L and CD40 within treated tumors were critical because tumor suppression was abrogated by coadministration to the tumors of neutralizing monoclonal antibody against CD40L along with the DCs. Finally, in vivo depletion and knockout mice experiments demonstrated that tumor regression produced by this combination therapy depends on CD8+ T cells, but not on CD4+ T cells. These findings should be useful in designing strategies for use of DCs and AdmCD40L in cancer immunotherapy.
authors: Department of Medicine, Weill Medical College of Cornell University New York, New York 10021, USA.
authors: T
authors: T
authors: Kikuchi
authors: N
authors: N
authors: Miyazawa
authors: M A
authors: MA
authors: Moore
authors: R G
authors: RG
authors: Crystal
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology / Q000628:therapy; D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D019013:CD40 Antigens / Q000276:immunology; D023201:CD40 Ligand / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D002455:Cell Division / Q000276:immunology; D003110:Colonic Neoplasms / Q000276:immunology / Q000628:therapy; D003713:Dendritic Cells / Q000276:immunology* / Q000637:transplantation; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics; D016219:Immunotherapy, Adoptive; D015552:Injections, Intralesional; D008546:Melanoma, Experimental / Q000276:immunology / Q000628:therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009374:Neoplasms, Experimental / Q000235:genetics / Q000276:immunology* / Q000628:therapy*; D016176:T-Lymphocyte Subsets / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
chemical_list: D019013:CD40 Antigens; D023201:CD40 Ligand